|Bid||300.51 x 800|
|Ask||300.89 x 800|
|Day's range||297.41 - 300.79|
|52-week range||208.95 - 304.36|
|PE ratio (TTM)||11.77|
|Earnings date||1 Aug 2018 - 6 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||321.67|
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, at 10 AM , in New York, NY.
On a per-share basis, the Hercules, California-based company said it had net income of $21.77. Earnings, adjusted for one-time gains and costs, came to $1.17 per share. The maker of instruments used in ...
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2018.
An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2018 on Tuesday, May 8, 2018, following the close of the market.
We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.